Researchers have conducted trials with mice by injecting a specific antibody fragment against soluble aggregates of the Ab peptide, responsible for the toxicity and cell death characteristic of Alzheimer’s disease. The beneficial effects were seen at the behavioural, cellular and molecular levels five days after an intraperitoneal dose was administered.